Tag: peptide and oligonucleotide cdmo market data

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Peptide And Oligonucleotide CDMO Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

The peptide and oligonucleotide cdmo market size has shown rapid expansion in recent years. It is anticipated to increase from $2.42 billion in 2025 to $2.7 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.9%. This historical growth can be attributed to several factors, including the surge in peptide-based therapeutics, the increasing complexity associated with synthetic oligonucleotides, the restricted in-house manufacturing capabilities among drug developers, the growing demands for regulatory compliance, and the early embrace of antisense and peptide drugs.

The peptide and oligonucleotide cdmo market size is poised for significant expansion in the upcoming years, with projections indicating it will reach $4.03 billion in 2030, growing at a compound annual growth rate (CAGR) of 10.5%. This anticipated growth can be attributed to the expanding pipelines of oligonucleotide therapeutics, increased investment in rare disease and oncology drugs, a rising need for swift production of clinical trial materials, a growing inclination towards specialized CDMO partnerships, and progress in solid-phase synthesis technologies. Major developments foreseen during this period include a surge in the outsourcing of peptide and oligonucleotide manufacturing, an escalating demand for cGMP-compliant complex molecule production, the expansion of comprehensive development and manufacturing services, an increased focus on high-potency and high-purity therapeutics, and the broader adoption of scalable and flexible manufacturing platforms.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=75236026&type=smp&name=Peptide%20And%20Oligonucleotide%20CDMO%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Peptide And Oligonucleotide CDMO Market Opportunity Drivers: What’s Unlocking New Revenue Potential?

The increasing acceptance of personalized medicine is anticipated to significantly advance the peptide and oligonucleotide CDMO markets in the foreseeable future. Personalized medicine defines a healthcare methodology that customizes medical decisions and therapeutic approaches to specific individual attributes, such as genetics, environmental factors, and lifestyle. This rising embrace of personalized medicine can be attributed to several elements, including breakthroughs in genomic technologies, an enhanced comprehension of disease mechanisms at a molecular level, and the demand for more effective and targeted treatment options uniquely suited to patients’ genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are pivotal in personalized medicine, as they produce customized therapeutic peptides and oligonucleotides precisely tailored to individual patient needs. A notable example is from February 2024, where, according to the Personalized Medicine Coalition, a UK-based organization dedicated to promoting personalized medicine, the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, a rise from 6 in 2022. Hence, the increasing adoption of personalized medicine is fundamentally propelling the expansion of the peptide and oligonucleotide CDMO market.

Peptide And Oligonucleotide CDMO Market Segments: Where Is Growth Concentrated?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

Peptide And Oligonucleotide CDMO Market Innovation Trends Shaping Future Development

Leading firms in the peptide and oligonucleotide CDMO market are prioritizing the formation of strategic alliances to improve their range of services, broaden their technological capacities, and extend their market presence. Such partnerships, particularly for peptide development and production, signify joint ventures between two entities dedicated to creating and manufacturing peptide-based treatments. An example of this is the collaboration in May 2023 between PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), and Numaferm GmbH, a Germany-based biotechnology firm, specifically for peptide development and production. The objective of this alliance is to leverage PolyPeptide’s cGMP manufacturing capabilities and market penetration, combined with Numaferm’s specialized knowledge in sustainable peptide manufacturing and biochemical production systems. Their joint focus is on exploring and developing appropriate peptide candidates, aiming for a more environmentally friendly production of peptide-based APIs.

Peptide And Oligonucleotide CDMO Market Key Participants And Competitive Landscape

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

View The Full Peptide And Oligonucleotide CDMO Market Report:

https://thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Peptide And Oligonucleotide CDMO Market Largest Region By Revenue And Market Share

North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Peptide And Oligonucleotide CDMO Market Growth From $2.7 Billion In 2026 To $4.02 Billion By 2030 At A CAGR Of 10.5%

The market for peptide and oligonucleotide CDMO services has experienced significant expansion in recent years, with projections indicating growth from $2.42 billion in 2025 to $2.7 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.9%. This historical uptick is largely driven by several factors, including the rise of peptide-based therapeutics, the growing intricacy of synthetic oligonucleotides, constrained in-house production capacities among drug developers, heightened regulatory compliance demands, and the early-stage adoption of antisense and peptide-based drugs.

The market size for peptide and oligonucleotide CDMOs is projected to experience substantial expansion over the coming years. By 2030, it is set to reach $4.03 billion, reflecting a compound annual growth rate (CAGR) of 10.5%. This anticipated growth during the forecast period is driven by factors such as the broadening of oligonucleotide therapeutic pipelines, heightened investment in treatments for rare diseases and oncology, an increasing need for swift production of clinical trial materials, a growing preference for partnerships with specialized CDMOs, and enhancements in solid-phase synthesis technologies. Key emerging trends expected in this period include the growing tendency to outsource the manufacturing of peptides and oligonucleotides, rising demand for cGMP-compliant production of complex molecules, the broadening of comprehensive development and manufacturing service offerings, a strengthened focus on high-potency and high-purity therapeutic options, and a greater uptake of scalable and flexible manufacturing systems.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Peptide And Oligonucleotide CDMO Market Growth Factors Supporting Long-Term Expansion

The increasing uptake of personalized medicine is set to drive expansion in the peptide and oligonucleotide CDMO markets moving forward. Personalized medicine is a healthcare strategy that customizes medical decisions and therapies based on individual traits like genetics, environment, and lifestyle. This trend is gaining momentum due to factors such as progress in genomic technologies, deeper insights into disease mechanisms at the molecular level, and a rising need for more effective, targeted treatments aligned with patients’ genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are vital to this approach, as they produce custom therapeutic peptides and oligonucleotides designed for specific patient needs. For example, in February 2024, the Personalized Medicine Coalition, a UK-based group advocating for personalized medicine, reported that the FDA’s Center for Drug Evaluation and Research (CDER) approved 16 new personalized therapies for rare disease patients, compared to 6 in 2022. Consequently, the growing embrace of personalized medicine is fueling the growth of the peptide and oligonucleotide CDMO market.

Peptide And Oligonucleotide CDMO Market Segment Landscape: Which Areas Lead Market Development?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

Peptide And Oligonucleotide CDMO Market Industry Trends Shaping Future Revenue Growth

Key players in the peptide and oligonucleotide CDMO space are increasingly emphasizing strategic collaborations to broaden their service portfolios, strengthen their technological expertise, and extend their market presence. Such alliances for peptide development and production involve formal agreements between two entities committed to the creation and manufacturing of peptide-based drugs. A notable example occurred in May 2023, when PolyPeptide Group AG—a contract development and manufacturing organization based in the US—formed a partnership with Germany’s biotechnology firm Numaferm GmbH, specifically targeting peptide development and manufacturing. This collaboration is designed to leverage PolyPeptide’s cGMP manufacturing infrastructure and market reach, alongside Numaferm’s specialized knowledge in sustainable peptide production and biochemical platforms. Together, they aim to investigate the development of promising peptide candidates, with a focus on achieving more environmentally friendly production of active pharmaceutical ingredients.

Peptide And Oligonucleotide CDMO Market Industry Leaders And Market Competition

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Access The Complete Peptide And Oligonucleotide CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Peptide And Oligonucleotide CDMO Market Global Footprint: Which Region Holds Market Leadership?

North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Much Larger Will The Peptide And Oligonucleotide CDMO Market Become By 2030 Compared To 2026?

The peptide and oligonucleotide CDMO market has experienced significant expansion in recent years. It is projected to grow from $2.42 billion in 2025 to $2.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.9%. The growth observed in the past can be attributed to several factors including the increase in peptide-based therapeutics, the rising complexity of synthetic oligonucleotides, the limited in-house manufacturing capabilities of drug developers, the growing demands for regulatory compliance, and the early adoption of antisense and peptide drugs.

The peptide and oligonucleotide cdmo market size is anticipated to undergo significant growth over the coming years. It is projected to achieve a valuation of $4.03 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 10.5%. This expansion during the forecast period is propelled by factors such as the broadening of oligonucleotide therapeutics pipelines, increased financial commitment to rare disease and oncology medications, an escalating requirement for expeditious clinical trial material manufacturing, an increasing inclination towards specialized CDMO alliances, and advancements in solid-phase synthesis techniques. Prominent developments expected in the forecast timeframe involve an uptick in the outsourcing of peptide and oligonucleotide production, a rising need for cGMP-compliant complex molecule manufacturing, the extension of comprehensive development and manufacturing services, an amplified emphasis on high-potency and high-purity therapeutics, and a greater embrace of scalable and adaptable manufacturing platforms.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

Which Growth Factors Are Strengthening The Peptide And Oligonucleotide CDMO Market Landscape?

The increasing acceptance of personalized medicine is anticipated to stimulate the expansion of the peptide and oligonucleotide CDMO markets in the coming period. Personalized medicine constitutes a healthcare methodology that customizes medical judgments and therapies to individual attributes, such as genetics, environment, and lifestyle. The rising uptake of personalized medicine is attributable to several elements, including breakthroughs in genomic technologies, enhanced comprehension of disease mechanisms at the molecular level, and the demand for more efficacious and targeted treatment options specifically adapted to individual patients’ genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a vital function in personalized medicine by manufacturing bespoke therapeutic peptides and oligonucleotides designed for specific patient requirements. For instance, in February 2024, according to the Personalized Medicine Coalition, a UK-based organization promoting the adoption of personalized medicine, the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, an increase from 6 in 2022. Consequently, the expanding adoption of personalized medicine is propelling the growth of the peptide and oligonucleotide CDMO market.

What Segment Categories Are Evaluated In The Peptide And Oligonucleotide CDMO Market Study?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

What Trends Are Influencing The Future Of The Peptide And Oligonucleotide CDMO Market?

Leading companies operating within the peptide and oligonucleotide CDMO market are concentrating on forging strategic alliances to bolster their service offerings, expand their technological capabilities, and enhance their market penetration. Peptide development and production partnerships involve collaborative agreements between two organizations focused on advancing and manufacturing peptide-based therapeutics. For instance, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), established a partnership with Numaferm GmbH, a Germany-based biotechnology company, for peptide development and production. This alliance aims to utilize PolyPeptide’s cGMP manufacturing capacities and market access, combined with Numaferm’s expertise in sustainable peptide manufacturing and biochemical production platforms. The partnership is dedicated to jointly exploring the development of suitable peptide candidates with the objective of achieving more sustainable production of peptide-based APIs.

Who Are The Businesses Driving Activity In The Peptide And Oligonucleotide CDMO Market?

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Access The Complete Peptide And Oligonucleotide CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Regional Market Leads The Peptide And Oligonucleotide CDMO Market?

North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Peptide And Oligonucleotide CDMO Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

Browse Through More Reports Similar to the Global Peptide And Oligonucleotide CDMO Market 2026, By The Business Research Company

Peptide And Oligonucleotide Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Oligonucleotides Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Peptide And Oligonucleotide CDMO Market Progress Between 2026 And 2030?

The size of the peptide and oligonucleotide cdmo market has expanded significantly over recent years. It is projected to further increase from $2.42 billion in 2025 to $2.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.9%. This historical expansion can be ascribed to several factors, including the growth in peptide-based therapeutics, the increasing complexity of synthetic oligonucleotides, the limited in-house manufacturing capabilities of drug developers, rising regulatory compliance requirements, and the early adoption of antisense and peptide drugs.

The peptide and oligonucleotide CDMO market size is poised for substantial growth in the upcoming years. It is projected to expand to $4.03 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.5%. This anticipated growth during the forecast period is driven by factors such as the expansion of oligonucleotide therapeutics pipelines, increasing investment in rare disease and oncology medications, a rising demand for swift clinical trial material production, a growing preference for specialized CDMO collaborations, and advancements in solid-phase synthesis technologies. Significant trends for the forecast period include an increase in the outsourcing of peptide and oligonucleotide manufacturing, a growing need for cGMP-compliant complex molecule production, the expansion of comprehensive end-to-end development and manufacturing services, an amplified focus on high-potency and high-purity therapeutics, and a greater adoption of scalable and flexible manufacturing platforms.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

Which Important Drivers Are Guiding The Peptide And Oligonucleotide CDMO Market Growth?

The expanding adoption of personalized medicine is anticipated to drive the growth of the peptide and oligonucleotide CDMO markets moving forward. Personalized medicine refers to a healthcare approach that tailors medical decisions and treatments to individual characteristics, including genetics, environment, and lifestyle. The increasing uptake of personalized medicine is attributed to several factors such as advancements in genomic technologies, an enhanced understanding of disease mechanisms at the molecular level, and the demand for more effective and targeted treatment options customized to individual patients’ genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a critical role in personalized medicine by producing customized therapeutic peptides and oligonucleotides specifically for individual patient needs. For instance, in February 2024, according to the Personalized Medicine Coalition, a UK-based organization promoting the adoption of personalized medicine, the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, an increase from 6 in 2022. Therefore, the growing adoption of personalized medicine is fueling the growth of the peptide and oligonucleotide CDMO market.

What Are The Different Segment Types In The Peptide And Oligonucleotide CDMO Market Segment Breakdown?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

Which Trends Are Contributing To Changes In The Peptide And Oligonucleotide CDMO Market?

Leading firms within the peptide and oligonucleotide CDMO market are prioritizing the formation of strategic alliances to improve their service provisions, broaden their technological capacities, and extend their presence in the market. Such partnerships, centered on peptide development and production, represent collaborative arrangements between two entities dedicated to creating and producing therapeutics derived from peptides. A notable example is the collaboration in May 2023, where PolyPeptide Group AG, a US-headquartered contract development and manufacturing organization (CDMO), formed a partnership with Numaferm GmbH, a biotechnology firm based in Germany, for the purpose of peptide development and production. This alliance seeks to leverage PolyPeptide’s cGMP manufacturing capabilities and market entry, alongside Numaferm’s specialized knowledge in sustainable peptide manufacturing and biochemical production platforms. The collaboration’s primary objective is to jointly investigate the creation of appropriate peptide candidates, with the ultimate aim of achieving more environmentally friendly production of active pharmaceutical ingredients (APIs) based on peptides.

Who Are The Well-Known Companies In The Peptide And Oligonucleotide CDMO Market?

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Get The Full Peptide And Oligonucleotide CDMO Market Report:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Region Holds The Highest Market Share In The Peptide And Oligonucleotide CDMO Market?

North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Peptide And Oligonucleotide CDMO Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Browse Through More Reports Similar to the Global Peptide And Oligonucleotide CDMO Market 2026, By The Business Research Company

Peptide And Oligonucleotide Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Oligonucleotides Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Peptide And Oligonucleotide CDMO Market Projected To Become By 2030 Based On Its 2026 Valuation?

The market for peptide and oligonucleotide CDMO services has expanded considerably over recent years. This market is projected to expand from $2.42 billion in 2025 to $2.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.9%. Historically, this expansion has been driven by several factors, including the rise in peptide-based therapeutics, the growing intricacy of synthetic oligonucleotides, drug developers’ constrained in-house manufacturing capacities, increasingly stringent regulatory compliance demands, and the initial uptake of antisense and peptide drugs.

The peptide and oligonucleotide cdmo market size is anticipated to undergo significant expansion over the next few years, with projections indicating it will reach $4.03 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.5%. This growth throughout the forecast period is propelled by factors such as the expanding pipelines of oligonucleotide therapeutics, increased investment in drugs for rare diseases and oncology, a heightened demand for rapid production of clinical trial materials, a growing preference for specialized CDMO partnerships, and continuous advancements in solid-phase synthesis technologies. Furthermore, notable trends expected in this period include an increase in the outsourcing of peptide and oligonucleotide manufacturing, a rising need for CGMP-compliant production of complex molecules, the expansion of comprehensive end-to-end development and manufacturing services, a sharpened focus on high-potency and high-purity therapeutics, and a wider adoption of scalable and flexible manufacturing platforms.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

What Major Growth Drivers Are Shaping The Outlook Of The Peptide And Oligonucleotide CDMO Market?

The increasing integration of personalized medicine is projected to fuel expansion within the peptide and oligonucleotide CDMO markets in the future. This healthcare approach involves customizing medical decisions and therapies based on distinct individual traits like genetics, environment, and lifestyle. Its rising popularity stems from various elements, including breakthroughs in genomic technologies, an enhanced comprehension of disease mechanisms at a molecular scale, and a need for more potent and specific treatment pathways designed for individual patients’ genetic makeup and medical backgrounds. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are pivotal in personalized medicine, creating bespoke therapeutic peptides and oligonucleotides to meet specific patient requirements. An example of this trend is evident in February 2024, as the Personalized Medicine Coalition, a UK-based organization promoting personalized medicine adoption, noted that the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, an increase from 6 in 2022. Consequently, the expanding embrace of personalized medicine is stimulating market expansion for peptide and oligonucleotide CDMOs.

What Segment Groups Are Identified Within The Peptide And Oligonucleotide CDMO Market?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

What Trends Are Advancing Progress In The Peptide And Oligonucleotide CDMO Market?

Leading companies within the peptide and oligonucleotide CDMO market are concentrating on establishing strategic collaborations to improve their service portfolios, expand their technological proficiency, and extend their market influence. Partnerships for peptide development and production denote cooperative agreements between two entities dedicated to the advancement and manufacturing of peptide-based therapeutic products. For example, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), entered into a partnership with Numaferm GmbH, a Germany-based biotechnology company, for the development and production of peptides. This alliance seeks to utilize PolyPeptide’s cGMP manufacturing capacities and market access, alongside Numaferm’s specialized knowledge in sustainable peptide manufacturing and biochemical production platforms. The collaboration is centered on jointly exploring the creation of appropriate peptide candidates with the objective of achieving more sustainable production of peptide-based APIs.

Which Companies Hold Significant Positions In The Peptide And Oligonucleotide CDMO Market?

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Read the full peptide and oligonucleotide cdmo market report here:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Regions Are Projected To Dominate The Peptide And Oligonucleotide CDMO Market In The Coming Years?

North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Peptide And Oligonucleotide CDMO Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15892&type=smp

Browse Through More Reports Similar to the Global Peptide And Oligonucleotide CDMO Market 2026, By The Business Research Company

Peptide And Oligonucleotide Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Oligonucleotides Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the peptide and oligonucleotide cdmo market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Peptide And Oligonucleotide CDMO Market reach by 2030 starting from 2026 levels?

The peptide and oligonucleotide cdmo market size has experienced rapid growth in recent years. It is anticipated to increase from $2.42 billion in 2025 to $2.7 billion in 2026, registering a compound annual growth rate (CAGR) of 11.9%. The historical expansion of this market can be attributed to the rise of peptide-based therapeutics, the increasing complexity of synthetic oligonucleotides, drug developers’ limited in-house manufacturing capabilities, escalating regulatory compliance requirements, and the early adoption of antisense and peptide drugs.

The market for peptide and oligonucleotide contract development and manufacturing organizations (CDMO) is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $4.03 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.5%. Factors contributing to this anticipated growth include the broadening pipelines for oligonucleotide therapeutics, heightened investment in treatments for rare diseases and oncology, a surge in the need for quick production of clinical trial materials, an increasing inclination towards specialized CDMO collaborations, and continuous improvements in solid-phase synthesis technologies. Key trends expected during the forecast period encompass a rise in the outsourcing of peptide and oligonucleotide manufacturing, an escalating demand for the production of complex molecules that adhere to cGMP standards, the expansion of comprehensive end-to-end development and manufacturing solutions, a heightened emphasis on therapeutic agents with high potency and purity, and an increased embrace of manufacturing platforms that are both scalable and flexible.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

Which Drivers Are Influencing Long-Term Growth In The Peptide And Oligonucleotide CDMO Market?

The increasing embrace of personalized medicine is anticipated to fuel the expansion of the peptide and oligonucleotide CDMO markets in the future. This healthcare strategy customizes medical choices and therapies based on unique attributes like genetics, environmental factors, and lifestyle. Its rising acceptance stems from various elements, including breakthroughs in genomic technologies, a deeper comprehension of disease processes at the molecular level, and the need for more potent and specific treatment solutions designed for patients’ distinct genetic makeups and health records. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are pivotal in personalized medicine, creating bespoke therapeutic peptides and oligonucleotides to meet specific patient requirements. For example, in February 2024, the Personalized Medicine Coalition, a UK-based organization promoting the adoption of personalized medicine, reported that the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, a rise from 6 in 2022. Consequently, the expanding use of personalized medicine is propelling the development of the peptide and oligonucleotide CDMO market.

How Is The Peptide And Oligonucleotide CDMO Market Divided Into Segments?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

Which Innovation Trends Are Advancing Developments Within The Peptide And Oligonucleotide CDMO Market?

Leading companies operating within the peptide and oligonucleotide CDMO market are concentrating on forging strategic partnerships to enhance their service offerings, expand their technological proficiencies, and increase their market reach. Peptide development and production partnerships refer to collaborative agreements between two organizations focused on advancing and manufacturing peptide-based therapeutics. For example, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), collaborated with Numaferm GmbH, a Germany-based biotechnology company, for peptide development and production. This alliance seeks to leverage PolyPeptide’s cGMP manufacturing capacities and market access, alongside Numaferm’s expertise in sustainable peptide manufacturing and biochemical production platforms. The partnership is primarily focused on jointly exploring the development of appropriate peptide candidates with the aim of achieving more sustainable production of peptide-based APIs.

Which Key Market Players Are Investing In Expansion And Innovation Within The Peptide And Oligonucleotide CDMO Market?

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Regions Are Poised For Strategic Growth In The Peptide And Oligonucleotide CDMO Market?

North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Peptide And Oligonucleotide CDMO Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15892&type=smp

Browse Through More Reports Similar to the Global Peptide And Oligonucleotide CDMO Market 2026, By The Business Research Company

Peptide And Oligonucleotide Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Oligonucleotides Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the peptide and oligonucleotide cdmo market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Peptide And Oligonucleotide CDMO Market reach by 2030 starting from 2026 levels?

The peptide and oligonucleotide cdmo market size has experienced rapid growth in recent years. It is anticipated to increase from $2.42 billion in 2025 to $2.7 billion in 2026, registering a compound annual growth rate (CAGR) of 11.9%. The historical expansion of this market can be attributed to the rise of peptide-based therapeutics, the increasing complexity of synthetic oligonucleotides, drug developers’ limited in-house manufacturing capabilities, escalating regulatory compliance requirements, and the early adoption of antisense and peptide drugs.

The market for peptide and oligonucleotide contract development and manufacturing organizations (CDMO) is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $4.03 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.5%. Factors contributing to this anticipated growth include the broadening pipelines for oligonucleotide therapeutics, heightened investment in treatments for rare diseases and oncology, a surge in the need for quick production of clinical trial materials, an increasing inclination towards specialized CDMO collaborations, and continuous improvements in solid-phase synthesis technologies. Key trends expected during the forecast period encompass a rise in the outsourcing of peptide and oligonucleotide manufacturing, an escalating demand for the production of complex molecules that adhere to cGMP standards, the expansion of comprehensive end-to-end development and manufacturing solutions, a heightened emphasis on therapeutic agents with high potency and purity, and an increased embrace of manufacturing platforms that are both scalable and flexible.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

Which Drivers Are Influencing Long-Term Growth In The Peptide And Oligonucleotide CDMO Market?

The increasing embrace of personalized medicine is anticipated to fuel the expansion of the peptide and oligonucleotide CDMO markets in the future. This healthcare strategy customizes medical choices and therapies based on unique attributes like genetics, environmental factors, and lifestyle. Its rising acceptance stems from various elements, including breakthroughs in genomic technologies, a deeper comprehension of disease processes at the molecular level, and the need for more potent and specific treatment solutions designed for patients’ distinct genetic makeups and health records. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are pivotal in personalized medicine, creating bespoke therapeutic peptides and oligonucleotides to meet specific patient requirements. For example, in February 2024, the Personalized Medicine Coalition, a UK-based organization promoting the adoption of personalized medicine, reported that the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, a rise from 6 in 2022. Consequently, the expanding use of personalized medicine is propelling the development of the peptide and oligonucleotide CDMO market.

How Is The Peptide And Oligonucleotide CDMO Market Divided Into Segments?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

Which Innovation Trends Are Advancing Developments Within The Peptide And Oligonucleotide CDMO Market?

Leading companies operating within the peptide and oligonucleotide CDMO market are concentrating on forging strategic partnerships to enhance their service offerings, expand their technological proficiencies, and increase their market reach. Peptide development and production partnerships refer to collaborative agreements between two organizations focused on advancing and manufacturing peptide-based therapeutics. For example, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), collaborated with Numaferm GmbH, a Germany-based biotechnology company, for peptide development and production. This alliance seeks to leverage PolyPeptide’s cGMP manufacturing capacities and market access, alongside Numaferm’s expertise in sustainable peptide manufacturing and biochemical production platforms. The partnership is primarily focused on jointly exploring the development of appropriate peptide candidates with the aim of achieving more sustainable production of peptide-based APIs.

Which Key Market Players Are Investing In Expansion And Innovation Within The Peptide And Oligonucleotide CDMO Market?

Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Regions Are Poised For Strategic Growth In The Peptide And Oligonucleotide CDMO Market?

North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Peptide And Oligonucleotide CDMO Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=15892&type=smp

Browse Through More Reports Similar to the Global Peptide And Oligonucleotide CDMO Market 2026, By The Business Research Company

Peptide And Oligonucleotide Cdmo Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Oligonucleotides Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report

Peptide Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the antidepressants market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Antidepressants Market By The End Of 2029?

The peptide and oligonucleotide cdmo market has seen substantial growth in recent years. Its valuation is predicted to expand from $2.16 billion in 2024 to $2.42 billion in 2025, achieving a compound annual growth rate (CAGR) of 11.8%. This historical market expansion can be ascribed to an increase in demand for therapeutic agents, innovations in synthesis and manufacturing, trends towards personalized medicine, adherence to regulatory guidelines, and an elevated focus on antiviral peptides and mRNA vaccines, which highlights the promise of oligonucleotides in vaccine creation.

The peptide and oligonucleotide CDMO market is projected for significant expansion in the coming years. This market is anticipated to reach a valuation of $3.69 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 11.2%. This projected growth is driven by factors such as the increasing need for personalized medicine, breakthroughs in biotechnology, broader application areas, a rise in outsourcing activities, and the escalating prevalence of chronic illnesses. Key trends anticipated during this period encompass the development of personalized therapies, continuous technological improvements, challenges related to quality control, a push for global market expansion, and enhanced cooperation between biopharmaceutical firms.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

Which Business Drivers Are Underpinning The Growth Of The Antidepressants Market?

The increasing embrace of personalized medicine is anticipated to fuel expansion in the peptide and oligonucleotide CDMO markets in the future. This healthcare methodology involves customizing medical choices and therapies based on unique individual traits, including genetics, environmental factors, and lifestyle choices. Its rising acceptance stems from multiple elements like progress in genomic technologies, a deeper comprehension of disease processes at a molecular scale, and a need for more potent and precise therapeutic alternatives designed for patients’ specific genetic makeups and medical backgrounds. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are pivotal in personalized medicine, creating bespoke therapeutic peptides and oligonucleotides specifically for individual patient requirements. As an example, in February 2024, data from the Personalized Medicine Coalition, a UK-based entity advocating for personalized medicine, indicated that the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) sanctioned 16 novel personalized treatments for rare disease patients, an increase from 6 in 2022. Consequently, the expanding use of personalized medicine is propelling the advancement of the peptide and oligonucleotide CDMO market.

What Are The Principal Segment Types In The Antidepressants Market?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

How Are Industry Trends Steering The Expansion Of The Antidepressants Market?

Leading companies in the peptide and oligonucleotide CDMO market are concentrating on forging strategic partnerships to enhance their service offerings, expand technological capabilities, and broaden their market reach. Peptide development and production partnerships signify collaborative agreements between two entities focused on developing and manufacturing peptide-based therapeutics. For instance, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), collaborated with Numaferm GmbH, a Germany-based biotechnology company, for peptide development and production. This alliance aims to utilize PolyPeptide’s cGMP manufacturing capacities and market access, alongside Numaferm’s expertise in sustainable peptide manufacturing and biochemical production platforms. The partnership is dedicated to jointly exploring the development of suitable peptide candidates with the objective of achieving more sustainable production of peptide-based APIs.

Which Companies Are Contributing Significantly To The Antidepressants Market Growth?

Major companies operating in the peptide and oligonucleotide CDMO market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd., Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc., ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Region Offers The Most Opportunity For Antidepressants Market Expansion?

North America was the largest region in the peptide and oligonucleotide CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=15892&type=smp

Browse Through More Reports Similar to the Global Antidepressants Market 2025, By The Business Research Company

Biologics Cdmo Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Peptide Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Glycopeptide Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Peptide And Oligonucleotide CDMO Market From 2025 To 2034?

The peptide and oligonucleotide cdmo market has experienced significant expansion recently. Projections indicate its size will increase from $2.16 billion in 2024 to $2.42 billion in 2025, showing a compound annual growth rate (CAGR) of 11.8%. Historically, this expansion is a result of several factors, including an escalating need for therapeutic agents, innovations in synthesis and manufacturing processes, the emergence of personalized medicine, evolving regulatory frameworks, and a heightened emphasis on antiviral peptides and mRNA vaccines, which underscores the role of oligonucleotides in vaccine advancement.

The market for peptide and oligonucleotide CDMO services is projected to experience swift expansion over the coming years. By 2029, this market is anticipated to reach $3.69 billion, exhibiting a compound annual growth rate (CAGR) of 11.2%. This growth throughout the forecast period is driven by factors such as the rising need for personalized medicine, continuous advancements in biotechnology, a broader range of applications, a surge in outsourcing activities, and the increasing prevalence of chronic illnesses. Key trends expected during the same period encompass tailored therapies, ongoing technological improvements, hurdles in quality control, worldwide market expansion, and enhanced partnerships among biopharmaceutical entities.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

What Are The Top Growth Drivers Impacting The Peptide And Oligonucleotide CDMO Market Outlook?

The expanded use of personalized medicine is anticipated to fuel expansion within the peptide and oligonucleotide CDMO markets. This healthcare methodology involves customizing medical choices and therapies based on unique individual traits, including genetics, environmental factors, and lifestyle. Its increasing prevalence stems from multiple elements like progress in genomic technologies, enhanced comprehension of disease processes at a molecular scale, and a need for more potent and precise treatments specifically designed for patients’ genetic profiles and health backgrounds. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) are vital in personalized medicine as they produce bespoke therapeutic peptides and oligonucleotides to meet specific patient requirements. A case in point is that in February 2024, the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) sanctioned 16 novel personalized therapies for patients with rare diseases, an increase from 6 in 2022, as reported by the Personalized Medicine Coalition, a UK-based group advocating for personalized medicine’s adoption. Consequently, the expanding embrace of personalized medicine is stimulating growth in the peptide and oligonucleotide CDMO market.

What Are The Major Segment Categories Driving The Peptide And Oligonucleotide CDMO Market Growth?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

What Are The Major Trends Driving The Growth Of The Peptide And Oligonucleotide CDMO Market?

Leading companies in the peptide and oligonucleotide CDMO market are prioritizing the formation of strategic partnerships to enhance their service offerings, expand their technological capabilities, and increase their market presence. Peptide development and production partnerships involve collaborative agreements between two organizations focused on creating and manufacturing peptide-based therapeutics. For example, in May 2023, PolyPeptide Group AG, a US-based contract development and manufacturing organization (CDMO), collaborated with Numaferm GmbH, a Germany-based biotechnology company, for peptide development and production. This partnership aims to utilize PolyPeptide’s cGMP manufacturing capacities and market access, alongside Numaferm’s expertise in sustainable peptide manufacturing and biochemical production platforms. The collaboration is focused on jointly investigating the development of suitable peptide candidates with the goal of achieving more sustainable production of peptide-based APIs.

Which Industry Leaders Are Driving Innovation Across The Peptide And Oligonucleotide CDMO Market?

Major companies operating in the peptide and oligonucleotide CDMO market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd., Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc., ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Peptide And Oligonucleotide CDMO Market?

North America was the largest region in the peptide and oligonucleotide CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Request A Customized Version Of The Peptide And Oligonucleotide CDMO Market Report:

https://www.thebusinessresearchcompany.com/customise?id=15892&type=smp

Browse Through More Reports Similar to the Global Peptide And Oligonucleotide CDMO Market 2025, By The Business Research Company

Biologics Cdmo Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biologics-cdmo-global-market-report

Peptide Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Glycopeptide Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

How Will The Peptide And Oligonucleotide CDMO Market Valuation Change Between Now And 2029?

The market size for peptide and oligonucleotide cdmo has witnessed fast-paced growth in recent years. It is projected to expand from a value of $2.16 billion in 2024 to $2.42 billion in 2025, marking a compound annual growth rate (CAGR) of 11.8%. The notable growth in the historic period can be credited to several factors, including an increase in demand for therapeutic agents, improvements in synthesis and manufacturing processes, trends in personalized medicine, regulatory guidelines, and a heightened focus on antiviral peptides and mRNA vaccines, which underscore the potential of oligonucleotides in vaccine development.

In the coming years, the peptide and oligonucleotide cdmo market is predicted to witness an accelerated growth, escalating to a worth of $3.69 billion in 2029 with a compound annual growth rate (CAGR) of 11.2%. A surge in the requirements for personalized healthcare solutions, developments in biotech field, broadening applications, greater rate of outsourcing, and the rising prevalence of chronic illnesses contribute to this anticipated growth. The forecasted period also anticipates key trends such as customized therapies, technological evolution, challenges in quality management, international growth, and degrees of collaboration within biopharmaceutical firms increasing.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp

What Growth-Enabling Forces Are Impacting The Peptide And Oligonucleotide CDMO Market?

The advancement of personalized medicine, which individualizes medical decisions and treatments based on qualities like genetics, environment, and lifestyle, is poised to boost the growth of peptide and oligonucleotide CDMO markets. This rise in personalized medicine comes as a result of factors such as improved genomic technologies, deeper comprehension of disease mechanisms at the molecular level, and a need for more effective and targeted treatments customized to each patient’s unique genetic profile and medical history. In the realm of personalized medicine, the importance of peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) cannot be understated, as they are responsible for the creation of bespoke therapeutic peptides and oligonucleotides designed for individual patients. In a case reported in February 2024 by the Personalized Medicine Coalition, a UK-based advocacy group for the implementation of personalized medicine, the FDA’s Center for Drug Evaluation and Research (CDER) greenlighted 16 new personalized treatments for patients suffering from rare diseases, marking a considerable increase from the 6 approved in 2022. Hence, it’s clear that the ongoing surge in personalized medicine applications fuels the expansion of the peptide and oligonucleotide CDMO market.

How Is The Peptide And Oligonucleotide CDMO Market Segmented Across Key Categories?

The peptide and oligonucleotide cdmo market covered in this report is segmented –

1) By Product: Peptides, Oligonucleotides

2) By Service Type: Contract Development, Contract Manufacturing,

3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications

4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Others End Users

Subsegments:

1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services

2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services

What Key Trends Are Driving Growth In The Peptide And Oligonucleotide CDMO Market?

Leading firms in the peptide and oligonucleotide CDMO sector are establishing strategic alliances to improve their services, broaden their technological base, and enhance their market penetration. Partnerships in peptide development and production entail cooperative contracts between two entities aiming to develop and produce peptide-based treatments. For example, in May 2023, PolyPeptide Group AG, an American CDMO, teamed up with Numaferm GmbH, a biotech firm based in Germany, for peptide development and manufacturing. The objective of this partnership is to leverage PolyPeptide’s cGMP manufacturing capacities and market penetration, and Numaferm’s proficiency in sustainable peptide production and biochemical manufacturing platforms. The collaboration aims at joint exploration of potential peptide candidates for more eco-friendly production of peptide-based APIs.

Which Companies Are Contributing Significantly To The Peptide And Oligonucleotide CDMO Market Growth?

Major companies operating in the peptide and oligonucleotide CDMO market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd., Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc., ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/peptide-and-oligonucleotide-cdmo-global-market-report

Which Region Dominates The Peptide And Oligonucleotide CDMO Market Today?

North America was the largest region in the peptide and oligonucleotide CDMO market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=15892&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model